PDUFA Becomes US FDA's Billion Dollar Baby
Executive Summary
Second consecutive year of record workload levels drive substantial increase in FDA's prescription drug user fee revenue target for fiscal year 2019.
You may also be interested in...
FY 2019 Drug Development Drives FY 2021 User Fees Lower
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.
User Fee Delinquencies Rising At US FDA After PDUFA Redesign
Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.
PDUFA Workload Sets Records, But Inflation Generates More Revenue
The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.